A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2016
At a glance
- Drugs Pazopanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- Acronyms PAZOGIST
- 05 Apr 2016 Primary endpoint has been met. (Progression-free survival), as per article published in the Lancet Oncology.
- 05 Apr 2016 Results published in the Lancet Oncology
- 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.